Company News
CVS Prioritizes Biosimilars Over Stelara July
CVS Health announced it will favor lower‑cost biosimilars instead of J&J’s Stelara on its formularies starting July 1.
Caremark will switch to Sandoz’s Pyzchiva and Biocon’s Yesintek biosimilars, with
